

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>QUINN MICHAEL A</u> (Last) (First) (Middle) <u>RESMED INC.</u> <u>97 WATERLOO ROAD</u> (Street) <u>NORTH RYDE C3 2113</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>RESMED INC [RMD]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>05/20/2002</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
ResMed Common Stock	02/28/2006		C		1,650	A	\$30.3	1,650	I	Kaylara ATF Kaylara Family Trust ⁽²⁾
ResMed Common Stock	02/28/2006		C		1,650	A	\$30.3	1,650	I	Kaylara ATF Straflo ⁽²⁾
ResMed Common Stock								74,800	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
ResMed - 4% Convertible Subordinated Notes	\$30.3	05/20/2002		P		50,000		(1)	06/20/2006	ResMed Common Stock	1,650	\$91.9236	50,000	I	Kaylara ATF Kaylara Family Trust ⁽²⁾
ReMed - 4% Convertible Subordinated Notes	\$30.3	05/20/2002		P		50,000		(1)	06/20/2006	ResMed Common Stock	1,650	\$91.9236	50,000	I	Kaylara ATF Straflo ⁽²⁾
ResMed - 4% Convertible Subordinated Notes	\$30.3	02/28/2006		C			50,000	(1)	06/20/2006	ResMed Common Stock	1,650	\$91.9236	0	I	Kaylara ATF Kaylara Family Trust ⁽²⁾
ResMed - 4% Convertible Subordinated Notes	\$30.3	02/28/2006		C			50,000	(2)	06/20/2006	ResMed Common Stock	1,650	\$91.91	0	I	Kaylara ATF Straflo ⁽²⁾
ResMed Stock Options	(3)							(3)	(3)	ResMed Common Stock ⁽³⁾	(3)		195,400 ⁽³⁾	D	

Explanation of Responses:

1. Transaction represents the purchase of ResMed's 4% Convertible Subordinated Notes due 6/20/2006. The Notes can be converted into 33 shares of ResMed Common Stock per \$1,000 principal amount of Notes at a conversion price of \$30.30 per share.
2. The Note holders are Kaylara ATF Kaylara Family Trust and Kaylara ATF Straflo which are entities controlled by Michael Quinn.
3. Mr. Quinn also has stock options granted between between 1998 and 2005. Options are exercisable 1/3 each year beginning 1 year after date of grant and expire 10 years after the grant date. Number of options beneficially owned reflects ResMed's 2-for-1 stock split.

Remarks:Michael A. Quinn06/12/2006

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.